Healthy Extracts Inc.

What they do

Healthy Extracts operates through three subsidiaries: Bergamet (heart/immune health), UBN (brain health), and HE Gummy USA (contract manufacturing and formulation). The company sells proprietary and patented nutraceutical products primarily in the U.S. and also provides gummy manufacturing services to third parties. Its products have not been evaluated by the FDA.

Revenue drivers

• Bergamet — Offers heart and immune health products based on Citrus Bergamot; a principal revenue source alongside UBN.
• UBN — Brain health products including RELIEF for migraine sufferers; contributes to revenue but not separately broken out.
• Gummy USA (HE Gummy USA, Inc.) — Contract manufacturing and formulation services; acquired in October 2025, accelerated revenue growth and increased gross profit.

Recent performance

For fiscal year 2025, annual revenue was $4.5 million, up from $3.1 million in 2024. Net loss for 2025 was $881,119, slightly wider than the $840,671 loss in 2024. Operating cash flow turned positive in 2024 ($281,968) and continued at $165,520 in 2025. Quarterly revenue reached $1.7 million for the quarter ended December 31, 2025 and $1.6 million for the quarter ended March 31, 2026. As of March 31, 2026, cash was $164,385, with total assets of $27.3 million and shareholder equity of $24.0 million.

Strategy

Management focuses on increasing revenue, maintaining margins, and generating positive cash flow from existing operations, particularly Bergamet and UBN. The October 2025 acquisition of Gummy USA added manufacturing capabilities and expanded the business into contract manufacturing. The company intends to leverage its positions in high-growth nutraceutical categories (heart, brain, immune) and gummy delivery formats. It continues to acquire or develop products with mass consumer appeal.

Risks

• Single supplier dependency — Relies on an exclusive U.S. and Canada licensing and manufacturing agreement with GELS for gel technology; termination could disrupt manufacturing and increase costs.
• Not profitable — Company has not achieved profitability and expects to remain unprofitable in the near term; may suspend or cease operations if revenues are insufficient.
• Going concern risk — The company's ability to continue as a going concern is uncertain, as noted in the 10-K risk factors.
• Regulatory and FDA status — Products have not been evaluated by the FDA, and any regulatory scrutiny could harm the business.

Outlook

Management expects to continue benefiting from the Gummy USA acquisition, which has already accelerated revenue growth and improved gross profit. The company remains focused on increasing revenue and maintaining positive cash flow. It also points to strong market tailwinds in nutraceuticals, particularly gummy formats, heart health, and brain health. However, no specific forward guidance is provided.